Skip to main content
SpringerLink
Log in

GI cancer news from ASCO

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Chu E, Shulman KL, Zelt S, Cartwright T.Cost of chemotherapy for patients with metastatic colorectal cancer treated with capecitabine or 5-fluorouracil monotherapy. 2009 Gastrointestinal Cancers Symposium: abstr. 413, 15 Jan 2009. Available from: URL: http://www.asco.org

  2. Harley CR, Shetty S, Seal B, Heien H.Cost and mortality among stage IV colorectal cancer patients treated with FOLFOX or FOLFIRI. 2009 Gastrointestinal Cancers Symposium: abstr. 410, 15 Jan 2009. Available from: URL: http://www.asco.org

  3. Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, Dominguez S, Florentin V, Douillard J.Cost-minimization analysis of XELOX versus FOLFOX-6 as first-line treatment of metastatic colorectal cancer in France. 2009 Gastrointestinal Cancers Symposium: abstr. 460, 15 Jan 2009. Available from: URL: http://www.asco.org

  4. Chu E, Shi N, Wei W, Cartwright T.Costs associated with capecitabine or 5-fluorouracil monotherapy among patients with colorectal cancer in the adjuvant setting. 2009 Gastrointestinal Cancers Symposium: abstr. 422, 15 Jan 2009. Available from: URL: http://www.asco.org

  5. Field KM, Kosmider S, Murigu N, Hibbert M, Gibbs P.Dose rounding of chemotherapy treatment: what is the potential impact on treatment costs and is it acceptable to oncologists? 2009 Gastrointestinal Cancers Symposium: abstr. 407, 15 Jan 2009. Available from: URL: http://www.asco.org

  6. Grudé F, Roué V, Beauchamp C, Gamelin E, Robinet G, Metges J, Riou F.Real cost linked to the introduction of targeted therapies (bevacizumab, cetuximab) and conventional chemotherapies in the treatment of metastatic colorectal cancer. EpidigOuest 2008. 2009 Gastrointestinal Cancers Symposium: abstr. 330, 15 Jan 2009. Available from: URL: http://www.asco.org

  7. Bharthuar A, Kim FJ, Yang GY, Kuvshinoff BW, Iyer RV.Cost-benefit analysis of treatment modality for stage III pancreatic carcinoma: a single institution experience. 2009 Gastrointestinal Cancers Symposium: abstr. 268, 15 Jan 2009. Available from: URL: http://www.asco.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

GI cancer news from ASCO. Pharmacoecon. Outcomes News 571, 4–5 (2009). https://doi.org/10.2165/00151234-200905710-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905710-00008

Keywords

Search

Navigation